Eniyan Egfr Gene 29 awọn iyipada

Apejuwe kukuru:

A lo kit yii lati wa ni wiwa ohun deede ti awọn iyipada ti o wọpọ ni awọn exon 18-21 ti Egar Gaini ninu awọn ayẹwo esin naa ni awọn alaisan akàn ẹdọforo.


Awọn alaye ọja

Awọn aami ọja

Orukọ ọja

Hwts-TM0012A-Eniyan-eniyan Egfr Gene 29 Awọn Iwari Iyipada Disiwaju Kit (Floorcisecere PRR)

Onimọraciology

Akàn egan ti di fa fa ti awọn iku ala-aye ni kariaye, idẹruba ilera eniyan. Awọn iroyin alakan kekere ti ko ni kekere fun nipa 80% ti awọn alaisan akàn ẹdọfóró. Fun apẹẹrẹ jẹ ibi-iṣere ti o ṣe pataki julọ fun itọju ti akàn ẹdọforo kekere ẹdọ-ọwọ. The phosphorylation of EGFR can promote tumor cell growth, differentiation, invasion, metastasis, anti-apoptosis, and promote tumor angiogenesis. EGFR tyrosine kinase inhibitors (TKI) can block the EGFR signaling pathway by inhibiting EGFR autophosphorylation, thereby inhibiting the proliferation and differentiation of tumor cells, promoting tumor cell apoptosis, reducing tumor angiogenesis, etc., so as to achieve tumor targeted therapy. A large number of studies have shown that the therapeutic efficacy of EGFR-TKI is closely related to the status of EGFR gene mutation, and can specifically inhibit the growth of tumor cells with EGFR gene mutation. Genware fun ni apa kukuru ti chromosome 7 (7p12), pẹlu ipari gigun ti 200kb ati oriširiši ti awọn egbega 28. The mutated region is mainly located in exons 18 to 21, codons 746 to 753 deletion mutation on exon 19 accounts for about 45% and the L858R mutation on exon 21 accounts for about 40% to 45%. The NCCN Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer clearly states that EGFR gene mutation testing is required before EGFR-TKI administration. This test kit is used to guide the administration of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drugs, and provide the basis for personalized medicine for patients with non-small cell lung cancer. Iwe Kit yii nikan lo fun wiwa ti awọn iyipada to wọpọ ni awọn alaisan egrar ninu awọn alaisan pẹlu akàn ẹdọ-ọwọ kekere. Awọn abajade idanwo naa wa fun itọkasi ile-iwosan nikan ati pe ko yẹ ki o lo bi ipilẹ ti o tẹle fun itọju ti o jẹ alamọdaju ti awọn alaisan. Clinicians should consider the patient's condition, drug indications, and treatment The reaction and other laboratory test indicators and other factors are used to comprehensively judge the test results.

Ikanni

Fa

Awọn ohun elo imọ-ẹrọ

Ibi ipamọ Omi: ≤-18 ℃ ni dudu; Lyophilized: ≤30 ℃ ni dudu
Oju aye Omi: 9 oṣu; Lyophilized: ỌJỌ 12
Iru apẹrẹ Abala tusmoot tuntun, apakan ti o fọju, paraffin-ifibọ paraffind tabi apakan, omi ara tabi omi ara
CV <5.0%
Lto Iwoju esi ti ncleic acifer labẹ abẹlẹ ti 3n-iru, le steraft ṣe oṣuwọn oṣuwọn 1%
Alaye pataki Ko si irekọja ti o wa pẹlu irufẹ eniyan ti ara ẹni ti a ṣe sinu ati awọn oriṣi mi
Awọn ohun elo ti o wulo Lo awọn biosystems 7500 awọn eto PC-akoko akoko-akokoTi a lo Biosystems 7300 Awọn ọna PCR Awọn akoko

Awọn ọna ṣiṣe PC ti akoko gidi 5

Lightcycler® 480 Prch eto gidi

Eto PFX96 Akoko PRC

Iṣẹ sisan

5A96C5434dc358F19D21FE988959493


  • Ti tẹlẹ:
  • Itele:

  • Kọ ifiranṣẹ rẹ nibi ki o firanṣẹ si wa